25-05-2012

Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. ...

more

20-07-2009

Alnylam Pharmaceuticals, Inc. announced that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010. The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and ...

more

In Vitro and In Vivo Findings Published in the Journal PLoS Pathogens Identify Novel Host Targets Involved in Malaria Infection

13-11-2008

Alnylam Pharmaceuticals, Inc. and Cenix BioScience GmbH announced the publication of a new study in the journal PLoS Pathogens demonstrating in vitro and in vivo RNAi-mediated silencing of novel host factors involved in malaria infection. The work resulted from an ongoing malaria research ...

more

New research using RNAi technologies published on the first molecular link between malaria and the host cholesterol uptake pathway

15-09-2008

Cenix BioScience GmbH, Alnylam Pharmaceuticals, Inc. and the Lisbon-based biomedical research centre Instituto de Medicina Molecular (IMM) announced the publication of their collaborative study in Cell Host & Microbe, describing the discovery and in vivo validation of scavenger receptor BI ...

more

13-08-2008

Alnylam Pharmaceuticals, Inc. announced it has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, to investigate and characterize the molecular mechanisms underlying intracellular transport of small interfering RNA, ...

more

Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics

05-06-2008

Alnylam Pharmaceuticals, Inc. announced the closing of its investment in and completion of its expanded agreement with Tekmira Pharmaceuticals Corporation as a result of the achievement of Tekmira's business combination with Protiva Biotherapeutics Inc. which occurred effective May 30, 2008. ...

more

Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics

02-05-2008

Alnylam Pharmaceuticals, Inc. announced the publication of a new study in Nature Biotechnology by Alnylam scientists and collaborators from the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). The new research documents the design and ...

more

Mechanism for the in-vivo transport of siRNA

19-09-2007

RNA interference, a natural mechanism that inhibits the gene expression of individual genes in eukaryotic cells, is a major topic in modern biology. However, their potential was usable to only a limited extent in mammals because the mechanism for the uptake of small RNAs was unknown up to ...

more

Collaboration Focuses on RNAi Therapeutic Program for Huntington's Disease

01-08-2007

Medtronic, Inc. and Alnylam Pharmaceuticals, Inc. announced that the companies are advancing their collaboration initiated in February, 2005, following positive pre-clinical data generated under the initial joint technology development phase of the program. Under the terms of the agreement, ...

more

Alnylam to receive 331 million US dollars in upfront payments and equity investment

10-07-2007

Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics. The alliance will ...

more